Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
Status:
Terminated
Trial end date:
2019-10-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD
(Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process
leading to clinical type 1 diabetes in non-diabetic children with ongoing beta-cell
autoimmunity as indicated by positive islet autoantibodies.
Phase:
Phase 2
Details
Lead Sponsor:
Lund University
Collaborator:
Region Skane
Treatments:
Aluminum sulfate Autoantibodies Cholecalciferol Ergocalciferols Vitamin D Vitamins